Harmony Biosciences (HRMY) Misses Q3 EPS by 9c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates
November 12, 2020 8:00 AM ESTWAKIX® (pitolisant) Total Revenue of $45.6 Million for Third Quarter of 2020
Differentiated Product Profile Aligns with Unmet Medical Need
On Track to Initiate Phase 2 Trial in Patients with Prader-Willi Syndrome by Year End
Conference Call and Webcast to be held today at 8:30 a.m. Eastern Time
PLYMOUTH MEETING, Penn. and CHICAGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Harmony) (Nasdaq: HRMY), a pharmaceutical company... More
